Thursday, July 19, 2012
Researchers at the University of California, San Francisco, SeaChange Pharmaceuticals Inc. and the Novartis Institutes for BioMedical Research have
developed a computational approach for large-scale, automated prediction of
binding interactions between molecules and targets that have been associated
with adverse drug reactions.1 The method could help companies
improve R&D productivity by pointing to safety signals and helping
prioritize candidates in silico.
Lou, K.-J. SciBX 5(28); doi:10.1038/scibx.2012.721 Published online July
1. Lounkine, E. et al.
Nature; published online June 10, 2012; doi:10.1038/nature11159 Contact:
Brian K. Shoichet, University of California, San Francisco, Calif. e-mail: email@example.com
Contact: Laszlo Urban, Novartis Institutes for BioMedical Research,
Boston, Mass. e-mail: firstname.lastname@example.org
2. Keiser, M.J. et al.
Nat. Biotechnol. 25, 197-206 (2007)
3. Cain, C. BioCentury
20(28), A14; July 9, 2012
4. Keiser, M.J. et al.
Nature 462, 175-181 (2009)
5. Paul, S.M. et al.
Nat. Rev. Drug Discov. 9, 203-214 (2010)
AND INSTITUTIONS MENTIONED
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Novartis Institutes for BioMedical Research, Cambridge, Mass.
SeaChange Pharmaceuticals Inc., San Francisco, Calif.
University of California, San Francisco, Calif.